HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

Key Points

• HUTCHMED signed a deal with GSK worth up to approximately $1.3 billion for ex-China rights to HMPL-A830, including a $110 million upfront payment and potential tiered royalties.
• HMPL-A830 is a preclinical therapy conjugate designed to target EGFR-overexpressing tumor cells while delivering a KRAS payload, potentially addressing resistance to standalone KRAS inhibitors in colorectal, pancreatic and lung cancers.
• HUTCHMED will lead global Phase I development, after which GSK will assume responsibility outside China; GSK also received a right of first negotiation on another early-stage candidate from HUTCHMED’s ATTC platform.

HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.

Under the agreement, HUTCHMED will be responsible for global Phase I development of HMPL-A830. GSK will assume responsibility for development outside China after Phase I. If the therapy is commercialized, HUTCHMED would also receive tiered royalties.

Chairman and Non-Executive Director Dan Eldar said the agreement reflects the company’s strategy of building a globally competitive oncology portfolio through differentiated innovation and partnerships. He said HUTCHMED does not expect to bring every candidate to global markets using only internal resources and will pursue different structures depending on the asset, including retaining rights, licensing ex-China rights, joint development arrangements and global licensing agreements.

“This partnership we announced today is another validation and acceleration of international access that is central to our strategy,” Eldar said.

KRAS-EGFR Approach

Dr. Guangxiu Dai, Executive Vice President and Head of Discovery and Global Portfolio Management, described HMPL-A830 as an EGFR antibody linked through a cleavable linker to a novel small-molecule KRAS payload. The antibody is designed to target EGFR-overexpressing tumor cells, enter the cells and release the KRAS payload, while also directly blocking EGFR signaling.

Dai said KRAS mutations occur in approximately 30% of human cancers and are particularly relevant in colorectal, pancreatic and lung cancers. These tumor types also frequently overexpress EGFR, she said.

According to Dai, the company believes simultaneous EGFR and KRAS inhibition could address a mechanism of resistance seen with standalone KRAS inhibitors, in which tumors increase signaling through upstream tyrosine kinase receptors such as EGFR. HUTCHMED also believes targeted delivery of the payload could reduce systemic toxicity and potentially enable combination approaches with chemotherapy and other frontline standard treatments.

“By targeting both EGFR and KRAS at the exact same time, HMPL-A830 blocks the bypass pathway before the tumor can escape,” Dai said.

HUTCHMED said HMPL-A830 is also intended to validate its broader ATTC platform, which pairs novel target payloads with antibodies. Dai cited additional programs targeting PI3K/PIKK pathways across HER2 and EGFR targets, including HMPL-A251 and HMPL-A580.

Early Clinical Development Plans

During the webcast’s question-and-answer session, Dai said HUTCHMED plans to enroll patients with KRAS mutations across tumor types in Phase I testing, although colorectal, pancreatic and lung cancers are expected to represent the major tumor types included. The company plans to begin in later-line settings.

HUTCHMED subsequently intends to initiate combination studies and move toward first-line treatment settings in combination with chemotherapy or immuno-oncology treatments, Dai said. She added that the company sees potential for HMPL-A830 as either a monotherapy or a frontline combination option, though these statements reflected the company’s development expectations.

Cheng said GSK’s existing work in antibody-drug conjugates made HMPL-A830 relevant to its next-generation research and development efforts, describing ATTC as an advancement from ADC technology. He also said HUTCHMED has maintained discussions with multiple multinational pharmaceutical companies regarding potential collaborations involving its platform.

Additional GSK Negotiation Right

Cheng said GSK has secured a right of first negotiation regarding another early-stage candidate from HUTCHMED’s ATTC platform. He did not identify the asset or provide a development timeline, stating that the level of interest could evolve as development progresses and that any future transaction would be disclosed if completed.

Separately, Cheng referenced two recent positive Phase III trial readouts involving HUTCHMED and AstraZeneca. He said detailed progression-free survival and overall survival data are expected to be presented at a future academic conference. He also said HUTCHMED expects milestone and royalty income from commercialized indications, including tiered royalties of 9% to 13% on global sales for the SAFFRON trial and 30% royalties from AstraZeneca for specified indications in China.

About HUTCHMED (NASDAQ:HCM)

HUTCHMED NASDAQ: HCM is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED's integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED's commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source